Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthMontana Medicaid TMS Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentMontana Department of Public Health & Human ServicesPolicy 475

    Transcranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression

    Customize your policy alerts

    Sign up for Montana Department of Public Health & Human Services Policy 475 alerts

    Get alerted when Policy 475 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Montana Medicaid coverage, medical necessity, provider qualifications, service limits, documentation, and prior authorization for TMS in adults with severe major depressive disorder.

    Policy Summary
    PayerMontana Department of Public Health & Human Services
    PolicyTranscranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression
    Policy CodePolicy 475
    Change TypeNo material change
    Effective DateOctober 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for TMS and document that all medical necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    30 visitsMaximum acute treatment visits
    6 visitsMaximum taper sessions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 classesRequired antidepressant classes
    >50%Prior response threshold
    Semi-annualOutcome submission

    Medical Necessity and Coverage Requirements

    Initial or Repeat TMS Medical Necessity

    TMS is covered when all required criteria are met.

    Adult qualifying diagnosis: The member is 18 years of age or older and was diagnosed by a licensed physician or psychiatrist within the past 30 days with F32.2 or F33.2 Major Depressive Disorder, severe without psychotic features.Age >=18; diagnosis within 30 days

    Treatment-resistance or prior TMS response

    • Inadequate medication response: The member failed to demonstrate a clinically significant response to at least one medication trial from at least two antidepressant medication classes.At least 2 antidepressant classes
    • Medication intolerance: The member cannot tolerate two agents from two different medication classes with distinct side effects.2 agents from 2 classes
    • Prior TMS response: The member has a history of positive response to TMS during a previous depressive episode.

    Treatment and Provider Requirements

    The following clinical treatment history and delivery requirements must also be met.

    Prior evidence-based treatment: The record documents evidence-based psychotherapy and psychopharmacologic agents known to be effective for Major Depressive Disorder that failed to produce significant improvement, as determined by an evidence-based depressive symptom inventory.
    Qualified referral and supervision: The referral and any repeat-treatment referral are written by a licensed physician or psychiatrist who examined the member, reviewed the record, and has experience administering TMS; treatment is provided under that clinician's direct supervision.
    FDA-approved delivery: TMS is delivered using an FDA-approved device for Major Depressive Disorder, following the manufacturer's user-manual protocol and parameters unless a modification is supported by published scientific evidence.

    Transition from ECT or Crisis

    A transition from acute ECT or crisis care may be considered reasonable and necessary when the additional documentation requirement is met.

    ECT or crisis transition: If the member is receiving ECT in an acute setting or is in crisis, transition to TMS may be considered as a less invasive treatment option, provided medical necessity for ECT is documented in the member's file.

    This is a permissive consideration, not an automatic coverage pathway.

    Service Requirements and Treatment Limits

    Service delivery is limited as follows.

    Member choice and course limits: The member meets medical necessity requirements, chooses TMS as documented in the most current ITP, and receives no more than 30 visits for the acute course at up to 5 visits per week over 6 to 7 weeks, followed by a 2-week taper consisting of 6 taper sessions.30 acute visits; up to 5 per week; 6 taper sessions

    The same maximum course applies to initial treatment and relapse treatment.

    Progress monitoring: The attending physician or psychiatrist monitors and documents clinical progress using standardized, evidence-based rating scales.
    Repeat treatment review: Continued stay review is required for repeat acute treatment for relapse when the member responded to prior treatment, evidenced by more than 50 percent improvement on a standard depressive symptom rating scale.>50 percent improvement

    TMS is excluded when the current depressive episode includes acute or chronic psychotic symptoms or disorders, or when the member has schizophrenia, schizophreniform disorder, or schizoaffective disorder. It is also excluded when non-removable conductive, ferromagnetic, or other magnetic-sensitive metal is implanted in the head within 30 cm of the TMS magnetic coil.

    TMS is not considered reasonable and necessary when the member has specified neurologic conditions, including epilepsy, Parkinson’s disease, multiple sclerosis, cerebrovascular disease, dementia, or increased intracranial pressure; a history of repetitive or severe head trauma; a primary or secondary central nervous system tumor; another degenerative neurologic condition; or active substance use.

    Diagnosis and Coding Requirements

    Covered ICD-10 Diagnosis CodesICD-10Covered
    F32.2Major Depressive Disorder, single episode, severe without psychotic features
    F33.2Major Depressive Disorder, recurrent episode, severe without psychotic features
    Diagnosis recency
    Timing requirementDiagnosis must be made within the past 30 days.
    Diagnosing professionalDiagnosis must be made by a licensed physician or psychiatrist.
    Qualifying diagnosesF32.2 Major Depressive Disorder, single episode, severe without psychotic features; or F33.2 Major Depressive Disorder, recurrent episode, severe without psychotic features.
    Antidepressant class trials
    Minimum number of classesAt least two antidepressant medication classes.
    Trial requirementAt least one medication trial from each of at least two antidepressant medication classes.

    Authorization and Documentation Actions

    Prior Authorization

    Prior Authorization Required

    Obtain prior authorization before providing TMS. The authorization submission must document that the member meets all applicable medical-necessity criteria.

    • Prior authorization is required.
    • Include the diagnosis, qualifying treatment history, referral and supervision details, device/protocol information, and other supporting medical-necessity documentation.
    Prior Authorization

    Continued Review for Relapse Treatment

    For repeat acute treatment for relapse of depressive symptoms, obtain continued stay review. Continued treatment is supported when the member responded to prior TMS treatment as demonstrated by more than 50% improvement on a standard evidence-based depressive symptom rating scale.

    • Up to 30 visits may be authorized for the acute phase, followed by 6 taper visits.
    • Document the prior treatment response and the continued-stay rationale in the member’s file.

    Unsupported block type: documentation

    Policy Background

    Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain and improve symptoms of depression. Under this policy, TMS is an alternative for treatment-resistant depression when medication trials are ineffective or medication side effects are intolerable. Coverage is focused on adults with severe Major Depressive Disorder without psychotic features.

    Key Definition

    Transcranial Magnetic Stimulation (TMS)
    Treatment typeA noninvasive procedure for treatment-resistant depression.
    MechanismUses magnetic fields to stimulate nerve cells in the brain and improve symptoms of depression.
    Applicable useAn alternative when medication trials are not working or medication side effects are intolerable for the member.

    Covered Treatment Modality

    TMS

    TMS is available for adults meeting the policy's severe Major Depressive Disorder, treatment-resistance or prior-response, provider, device, documentation, prior authorization, and treatment-course requirements.

    TMS treatment modality: TMS is available for adults meeting the policy's severe Major Depressive Disorder, treatment-resistance or prior-response, provider, device, documentation, prior authorization, and treatment-course requirements.

    Exclusions and utilization limits apply.

    Treatment and Visit Limits

    TMS visit limits
    Maximum visits30 visits.
    FrequencyUp to 5 times per week.
    Acute-course durationOver a 6- to 7-week period.
    Taper6 taper sessions over 2 weeks.
    Repeat acute treatment limits
    Acute-phase limitMaximum 30 acute-phase visits for repeat treatment for relapse.
    Taper limitUp to 6 additional taper visits.
    Policy Summary
    PayerMontana Department of Public Health & Human Services
    PolicyTranscranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression
    Policy CodePolicy 475
    Change TypeNo material change
    Effective DateOctober 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for TMS and document that all medical necessity criteria are met.
    SourceLink
    On This Page
    Medical Necessity and Coverage RequirementsDiagnosis and Coding RequirementsAuthorization and Documentation ActionsPolicy BackgroundKey DefinitionCovered Treatment ModalityTreatment and Visit Limits
    Qualifying alternativeThe member may instead be unable to tolerate two agents from two different medication classes with distinct side effects, or have a history of positive response to TMS during a previous depressive episode.
    TMS coil metal exclusion
    Excluded implantConductive, ferromagnetic, or other magnetic-sensitive metal implanted in the member’s head that is non-removable.
    Distance limitThe implant must not be within 30 cm of the TMS magnetic coil.
    Coverage effectTMS is not covered and is considered not reasonable and necessary when this exclusion applies.
    Prior response for relapse treatment
    Applicable treatmentRepeat acute treatment for relapse of depressive symptoms.
    Required prior responseMore than 50 percent improvement in depressive symptoms on a standard rating scale.
    Review requirementContinued stay review is required when the member responded to prior treatment at this level.
    Acute treatment course
    Acute treatment visitsMaximum 30 visits.
    Weekly frequencyUp to 5 visits per week.
    Treatment durationOver a 6- to 7-week period.
    TaperA 2-week taper consisting of 6 taper sessions.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Documentation Required

    Maintain Treatment and Outcome Records

    Maintain records supporting medical necessity, treatment selection, clinical progress, and outcomes throughout the course of care.

    • Document that the member meets the medical-necessity requirements and has chosen TMS in the most current ITP.
    • For initial or relapse treatment, document the treatment course of up to 30 visits over 6–7 weeks, up to 5 visits per week, followed by a 2-week taper of 6 sessions.
    • The attending physician or psychiatrist must monitor and document clinical progress using standardized, evidence-based rating scales.
    • Track and submit the outcome measures in Policy 475qm to Montana Medicaid semi-annually.
    Denial Risk

    Exclusion or Contraindication

    TMS is not covered and is not considered reasonable and necessary when any exclusion or contraindication below is present.

    • Acute or chronic psychotic symptoms or disorders are present in the current depressive episode.
    • Non-removable conductive, ferromagnetic, or other magnetic-sensitive metal is implanted in the head within 30 cm of the TMS coil.
    • The member has Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder.
    • The member has epilepsy, Parkinson’s disease, multiple sclerosis, cerebrovascular disease, dementia, increased intracranial pressure, a history of repetitive or severe head trauma, a primary or secondary central nervous system tumor, or another degenerative neurologic condition.
    • Active substance use is present.
    Continued stay reviewRequired for repeat acute treatment for relapse when prior treatment produced more than 50 percent improvement on a standard depressive symptom rating scale.